Facebook
X
LinkedIn
ForwardInsight 2026: Vizient Cell, Gene and Specialty Symposium
Southlake, TX US
May 6, 2026 to May 7, 2026
The Vizient Cell, Gene & Specialty Symposium is an industry leading event that brings together thought leaders committed to the advancement of health-system pharmacy in the management, delivery, and optimization of advanced therapeutics, such as the ever-growing landscape of cell and gene therapies. You will hear clinical, operational, and business experts of leading providers, manufacturers, payers, and other stakeholders describe the opportunities and challenges of this field and what critical actions are required to preserve and expand access to these novel therapies. This symposium will also include updates on the latest in pipeline development, industry trends, numerous networking opportunities with thought leaders and experts of cell, gene and specialty therapies.
Learners will gain practical insights into how leading health systems are operationalizing cell and gene therapy programs across the care continuum. Through real-world case examples, the session will highlight approaches to governance, multidisciplinary coordination, and workflow design—from individual patient dose management to broader program scalability. Attendees will leave with actionable strategies to support safe, efficient, and sustainable delivery of advanced therapies within their organizations.
Target Audience
- Pharmacists
- Pharmacy Technicians
- Nurses
- Physicians
- Other healthcare professionals
Learning Objectives
At the conclusion of this activity, all participants should be able to:
- Describe key components of effective governance and multidisciplinary team structures used to support cell and gene therapy programs.
- Compare different operational models and workflows across health systems for managing the end-to-end delivery of advanced therapies.
- Identify common operational challenges and gaps in implementing cell and gene therapy programs, including coordination, infrastructure, and scalability considerations.
- Apply practical strategies to optimize workflows, roles, and processes that support safe, efficient, and sustainable delivery of cell and gene therapies within their organization.
At the conclusion of this activity, pharmacists should be able to:
- Describe key components of effective governance and multidisciplinary team structures used to support cell and gene therapy programs.
- Compare different operational models and workflows across health systems for managing the end-to-end delivery of advanced therapies.
- Identify common operational challenges and gaps in implementing cell and gene therapy programs, including coordination, infrastructure, and scalability considerations.
- Apply practical strategies to optimize workflows, roles, and processes that support safe, efficient, and sustainable delivery of cell and gene therapies within their organization.
At the conclusion of this activity, pharmacy technicians should be able to:
- Describe key components of effective governance and multidisciplinary team structures used to support cell and gene therapy programs.
- Compare different operational models and workflows across health systems for managing the end-to-end delivery of advanced therapies.
- Identify common operational challenges and gaps in implementing cell and gene therapy programs, including coordination, infrastructure, and scalability considerations.
- Apply practical strategies to optimize workflows, roles, and processes that support safe, efficient, and sustainable delivery of cell and gene therapies within their organization.
Horizontal Tabs
Hilton Dallas Southlake
1400 Plaza Place
Southlake, TX
76092
United States
FACULTY & PLANNERS
Faculty
Amanda Frick, PharmD
Senior Clinical Manager
Vizient
Senior Clinical Manager
Vizient
Danielle Pennock, PharmD
Clinical Coordinator, Gene Therapy
Johns Hopkins
Clinical Coordinator, Gene Therapy
Johns Hopkins
Emilie Aschenbrenner, PharmD
Pharmacy Lead for BMT and CGT
Froedtert
Pharmacy Lead for BMT and CGT
Froedtert
Casey Dugan, PharmD
VP, Pharmacy Services
Children’s Colorado
VP, Pharmacy Services
Children’s Colorado
Anahit Muscarella, PharmD
Program Director, High Cost Therapies
Vanderbilt
Program Director, High Cost Therapies
Vanderbilt
Aimee Ossman
VP, Policy
Children’s Hospital Association
VP, Policy
Children’s Hospital Association
John McLean
AVP, Managed Care Contracting
Penn Medicine
AVP, Managed Care Contracting
Penn Medicine
Jeff Wagner, PharmD
VP, Pharmacy and Respiratory
Texas Children’s Hospital
VP, Pharmacy and Respiratory
Texas Children’s Hospital
Rich Dyke, PharmD
Director, Pharmacy Business Operations
Children’s Hospital of Philadelphia
Director, Pharmacy Business Operations
Children’s Hospital of Philadelphia
Holly Kalb, PharmD
Pharmacy Revenue Cycle Manager
University of Rochester Medical Center
Pharmacy Revenue Cycle Manager
University of Rochester Medical Center
Matthew Ridge, CPhT
Manager, Pharmacy Business Operations
Cook Children’s Medical Center
Manager, Pharmacy Business Operations
Cook Children’s Medical Center
Jacob Keller, MHA
Director of Oncology Operations; Director, Cell & Gene Therapy
Duke University Health System
Director of Oncology Operations; Director, Cell & Gene Therapy
Duke University Health System
Seth Richards
Senior Director, Moffitt Medical Group
Moffitt Cancer Center
Senior Director, Moffitt Medical Group
Moffitt Cancer Center
Aaron Weston
System Administrative Officer, Cellular Therapy
Medical University of South Carolina (MUSC) Health
System Administrative Officer, Cellular Therapy
Medical University of South Carolina (MUSC) Health
Philip Almeter, PharmD
Chief Pharmacy Officer
UK HealthCare
Chief Pharmacy Officer
UK HealthCare
David Neil Toupin, MD
MD
UK HealthCare
MD
UK HealthCare
Jesse Cramer, PharmD
Manager, Clinical Pharmacy Services
Children’s Wisconsin
Manager, Clinical Pharmacy Services
Children’s Wisconsin
Pete Shea, PharmD
Pharmacy Director
Cincinnati Children’s Medical Center
Pharmacy Director
Cincinnati Children’s Medical Center
Olga Vlashyn, PharmD
Associate Director, Hematology / Oncology Pharmacy Services
Boston Medical Center
Associate Director, Hematology / Oncology Pharmacy Services
Boston Medical Center
Kristin Ferguson, PharmD
Senior Director, Strategic Operations: BMT & Cell Therapy
MedStar Georgetown Hospital
Senior Director, Strategic Operations: BMT & Cell Therapy
MedStar Georgetown Hospital
Janine Martino, PharmD
Pharmacist Specialist, BMT/IEC
UCSD
Pharmacist Specialist, BMT/IEC
UCSD
Colleen Dansereau, RN
VP, Emerging Therapies, Gene Therapy Operations
Boston Children’s
VP, Emerging Therapies, Gene Therapy Operations
Boston Children’s
Khang Ho, PharmD
Infusion Pharmacy Manager
Penn Medicine
Infusion Pharmacy Manager
Penn Medicine
Zahra Mahmoudjafari, PharmD
Clinical Pharmacy Manager
University of Kansas Health System
Clinical Pharmacy Manager
University of Kansas Health System
Carrie Marvill, RN
Associate Director
Penn Medicine
Associate Director
Penn Medicine
Delia Allen, PharmD
Medication Use Policy Coordinator
St. Jude Children’s Research Hospital
Medication Use Policy Coordinator
St. Jude Children’s Research Hospital
Jenny Craven, PharmD
Coordinator, Cell & Gene Therapy
UC Davis
Coordinator, Cell & Gene Therapy
UC Davis
Lindsey MacDonald, RN
CCTT Manager of Data Analytics
Penn Medicine
CCTT Manager of Data Analytics
Penn Medicine
Planners
Genevieve Hayes, PharmD, MS, BCPS
Senior Clinical Manager
Vizient, Inc.
Carina Dolan, PharmD
AVP, Clinical Oncology, Pharmacoeconomics & Market Insights
Vizient, Inc.
Ashley Hodges
Sr Event Marketing and Planning Director
Vizient, Inc.
Samantha Gordon, MS
CE Programs Manager
Vizient, Inc.
Marilu Kelly, MSN, RN, NPD-BC, CHCP
Director, Continuing Education
Vizient, Inc.
DISCLOSURE
As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.
Ineligible companies – those companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.
Disclosure Statements
Relevant Financial Relationships
Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.
Emilie Aschenbrenner, PharmD, speaker for this educational activity, is a speaker for AbbVie Inc., Astellas Pharma Inc., Bristol Myers Squibb, GlaxoSmithKline, Genmab A/S, Incyte, Sanofi, Syndax Pharmaceuticals, and a consultant for AbbVie Inc., Amgen Inc., Genmab A/S, Incyte, Invivyd, Inc., and Omeros Corporation.
Casey Dugan, PharmD, speaker for this educational activity, is an advisor for Neurogene Inc. and Sarepta Therapeutics, Inc.
Jeff Wagner, PharmD, speaker for this educational activity, is advisor for Neurogene Inc. and Omnicell.
Richard “Rich” Dyke, PharmD, speaker for this educational activity, is a consultant for Neurogene Inc. and RegenXBio Inc.
Jacob Keller, MHA, speaker for this educational activity, is advisor for Autolus Therapeutics, IOVANCE Biotherapeutics, Inc., Mesoblast Ltd, and Orca Bio.
Seth Richards, speaker for this educational activity, is a consultant for Autolus Therapeutics, Clarivate, Johnson & Johnson, Merck & Co., TScan Therapeutics, and a speaker for HMP Global.
Aaron Weston, speaker for this educational activity, is an advisor for Adaptimmune and Avalere Health.
David Neil Toupin, MD, speaker for this educational activity, is a principal/named investigator for Genentech.
Jesse Cramer, PharmD, speaker for this educational activity, has individual stocks and stock options with Capricor, Genetix Biotherapeutics Inc. (BlueBird Bio), Pfizer, Inc., and SELLAS Life Sciences Group, Inc.
Zahra Mahmoudjafari, PharmD, speaker for this educational activity, is a speaker/presenter for Genentech, Janssen Pharmaceuticals, Merck & Co., Pfizer, Inc., and Sanofi.
Carrie Marvill, RN, speaker for this educational activity, is a speaker/presenter for AstraZeneca.
Jennifer “Jenny” Craven, PharmD, speaker for this educational activity, is an advisor for Cencora, Inc. and CSL Behring.
All others in a position to control content for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Statement of Content Validity
Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.
FDA Off-Label Use
Faculty presenters are also expected to disclose any discussion of (1) off-label or investigational uses of FDA approved commercial products or devices or (2) products or devices not yet approved in the United States.
Off-label/unapproved drug uses or products are mentioned within this activity.
Low/absence of evidence-based topics are mentioned within this activity.
Disclaimer
The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.
Joint Accreditation Statement
In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Designation Statements
Interprofessional Continuing Education (IPCE)
This activity was planned by, and for, the healthcare team, and learners will receive 9.25 Interprofessional Continuing Education (IPCE) credits for learning and change.
Pharmacists (CPE)
Vizient, Inc. designates this live activity for a maximum of 9.25 contact hours for pharmacists.
Universal Activity Number: JA0006103-0000-26-028-L04-P
Pharmacy Technicians (CPE)
Vizient, Inc. designates this live activity for a maximum of 9.25 contact hours for pharmacy technicians.
Universal Activity Number: JA0006103-0000-26-028-L04-T
Physicians (CME)
Vizient, Inc. designates this live activity for a maximum of 9.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses (CNE)
This activity is designated for 9.25 contact hours.
Other Healthcare Professionals (General CE Credit)
Vizient, Inc. will award all other healthcare professionals who successfully complete the activity a Certificate of Participation. Various state license boards and credentialing bodies accept certificates of participation from accredited CE activities to meet CE requirements for license renewals and re-certification. It is the responsibility of the participant to contact their state licensing board and/or certifying body for verification on credit eligibility reciprocity.
Available Credit
- 9.25 ACPE Pharmacist
- 9.25 ACPE Pharmacy Technician
- 9.25 AMA PRA Category 1 Credit™
- 9.25 ANCC
- 9.25 General CE - Attendance
Select the “Obtain Credit” button to access the activity evaluation and to claim CE Credit.
Please Note:
- If the "Register/Take Course" tab is displayed instead of the "Obtain Credit" tab, you must first login to proceed with the credit claim process.
- This activity requires learners to confirm their attendance using an activity code. An Access Denied error message indicates that your attendance was not recorded via SMS text or QR code scanning.
Please click here to enter the code you received at the end of the activity to verify your attendance if you have not already done so: https://continuingeducation.vizientinc.com/code
Required Hardware/software
The Vizient CE Learner Portal is compatible with most modern web browsers (such as Firefox, Google Chrome, Microsoft Edge, Apple Safari) and can also be accessed with mobile devices.